← Back to Clinical Trials
Recruiting NCT06953232

NCT06953232 Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06953232
Status Recruiting
Phase
Sponsor Loughborough University
Condition Cardiovascular Diseases
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2025-09-30
Primary Completion 2026-10

Eligibility & Interventions

Sex Female only
Min Age 50 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Whey protein-enriched milk fat globule membrane supplementWhey protein-based supplement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2025-09-30 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In a single-blind, randomised, placebo-controlled crossover manner, this study aims to assess the impact of a high-fat mixed meal containing a whey protein (WP)-enriched milk fat globule membrane (MFGM) powdered ingredient on markers of heart and brain health in the fed state among middle-to-older-aged, postmenopausal women living with overweight and at moderate risk for cardiovascular disease. Participants will attend two \~8 hour study visits, where they will consume a high-fat meal containing a WP-enriched MFGM powdered ingredient or a placebo WP-based powdered ingredient. Each visit will involve anthropometric measurements and periodic assessments of heart health, including blood pressure and blood vessel stiffness measurements, blood sample collections, as well as computer-based tests measuring mood and cognition (brain function) over a 6-hour postprandial period.

Eligibility Criteria

Inclusion Criteria: * Apparently healthy postmenopausal women (not menstruating for 12 or more months) * Aged 50 - 75 years * BMI: 25 - 40 kg/m² * Moderate CVD risk * Recreationally active (\> 3 x 30 min moderate exercise per week) * Understands and is willing and able to comply with all study procedures including eating a high-fat breakfast meal * Fluent in written and spoken English * Access to, and able to use, the internet/computer/tablet device Exclusion Criteria: * Smoking (including vaping) * Diagnosed with cardiovascular disease or suffered myocardial infarction /stroke in the past twelve months * Existing or significant past medical history of any medical condition likely to affect the study outcomes e.g., diabetes, digestive, cancer or thyroidal disease, neurological disease (Alzheimer's disease, other form of dementia, mild cognitive impairment), or serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder), learning disorders (dyslexia) * Early or premature menopause resulting from medical conditions or undergoing surgery * Hormone replacement therapy within last 6 months * Prescribed medications likely to interfere with study outcomes (including lipid/cholesterol-lowering medications, including statins; blood thinners, antiplatelets (anticoagulants) such as heparin, etc.; medications for blood pressure; inflammation such as nonsteroidal anti-inflammatory drugs, aspirin, etc.; immune function, or lipid/carbohydrate metabolism) or prescribed antibiotics within the last three months * Use of antidepressant or anti-anxiety medication if it has changed in the last three months or expected to change within the 3-month study period * Taking vitamin, mineral, or fatty acid supplements (e.g., fish oil, calcium) or unwilling stop consuming these for the duration of the study (including sufficient washout period) * Working night shifts * Inaccessible veins for blood collection via cannulation * Unstable weight history (≥3 kg loss or gain in the previous 3 months) or planning or currently on a weight reduction scheme * Known allergy or intolerance to study food (including lactose intolerance, dairy, and wheat) * Being vegan or any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention or metabolic study * Excessive alcohol consumption: \>21 unit/wk (i.e., more than 10 and a half pints of beer or 21 small glasses of wine) * Currently taking part or have participated in another research study in the last two months (e.g., dietary intervention)

Contact & Investigator

Central Contact

Oonagh Markey, BSc, PhD

✉ o.markey@lboro.ac.uk

📞 +44 1509 222737

Frequently Asked Questions

Who can join the NCT06953232 clinical trial?

This trial is open to female participants only, aged 50 Years or older, up to 75 Years, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06953232 currently recruiting?

Yes, NCT06953232 is actively recruiting participants. Contact the research team at o.markey@lboro.ac.uk for enrollment information.

Where is the NCT06953232 trial being conducted?

This trial is being conducted at Loughborough, United Kingdom.

Who is sponsoring the NCT06953232 clinical trial?

NCT06953232 is sponsored by Loughborough University. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology